5 mg poeder en oplosmiddel voor oplossing voor injectie

DRUG2 trials

Sponsors

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Universitair Medisch Centrum Groningen

Conditions

Patients with biochemical recurrence after primary treatment of prostate cancer presenting with =<4 metastaseslow-volume metastatic castration-sensitive prostate cancer

Phase 3

Apa/Enza short study (Shortened 12 months duration of androgen receptor signalling agent in combination with androgen deprivation therapy in patients with low-volume metastatic castration-sensitive prostate cancer: a randomized nationwide trial

RecruitingCTIS2023-506698-36-00

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)low-volume metastatic castration-sensitive prostate cancer

Start: 2024-02-02Target: 400Updated: 2025-12-03

ADOPT; Androgen Deprivation therapy for Oligo-recurrent Prostate cancer in addition to radioTherapy

Not yet recruitingCTIS2024-511252-41-00

Universitair Medisch Centrum GroningenPatients with biochemical recurrence after primary treatment of prostate cancer presenting with =<4 metastases

Target: 280Updated: 2024-07-29